The goal of this study was to explore immunological strategies to increase local and systemic tumor control in patients receiving radiation therapy. In previous studies, interleukin-3 (IL-3) gene expression within murine tumors was shown to increase their response to irradiation through immune mechanisms. In this study, the efficacy of systemically administered IL-3 gene-transduced irradiated tumor cell vaccines was tested for their ability to augment radiation responses against established immunogenic (FSAR) and nonimmunogenic (FSAN) tumors. Vaccines of irradiated FSAR/FSAN or FSAN-JmIL-3/FSAR-JmIL-3 cells were given intraperitoneally just before and after local irradiation of parental tumors with diameters of 8 mm, as well as in two booster doses. The IL-3 gene-transduced tumor cell vaccines were more effective than the parental vaccines at delaying tumor growth after irradiation, although no complete cures resulted. Responses were largely specific to the tumor type, indicating that tumor-specific immunity was enhanced by IL-3 vaccine administration. When the experiment was repeated in the C3H/HeJ mice, which are deficient in tumor necrosis factor-␣ production, the vaccines were still effective, but less so than in C3H/HeN mice. Systemic IL-3 vaccine treatment increased intratumoral levels of intercellular adhesion molecule-1, Mac-1, EB22/5.3, tumor necrosis factor-␣, and IL-1 mRNA in irradiated tumors, indicating that cellular infiltration was part of the response. The study demonstrates that local radiation therapy can enhance the efficacy of genetically altered vaccine-based immunotherapy for cancer by decreasing tumor burden. At the same time, tumor cell vaccines may improve the cure rate of local radiation therapy by eliminating residual cancer cells. Although less effective than intratumoral gene expression, administration of IL-3 gene-transduced tumor cell vaccines is clinically a more feasible strategy that may be useful in situations in which the tumor load is small.
R adiation therapy, as a single modality, effectively controls many cancers but fails with others due to local recurrence or the development of tumor metastases outside the radiation field. Potential targets that could be exploited to improve local tumor control after radiation therapy include intrinsic pathways that cause tumor radioresistancy, 1 radioresistant tumor cells residing in hypoxic areas, 2, 3 or the tumor microvasculature. 4, 5 However, the dual aim of elimination of micrometastatic disease while improving local tumor control will require two-pronged strategies that combine radiation therapy with systemic treatment such as chemotherapy or immunotherapy.
Combining immunotherapy with radiation therapy has been attempted before. 6, 7 It seems logical because localized radiation delivery to a relatively small tumor volume, unlike chemotherapy or whole body irradiation, has little immunosuppressive effect on the immune system, although modest changes in peripheral white cell counts have been observed. Success has been modest, perhaps because the immunotherapy was aimed at increasing lymphocyte infiltration into the site receiving irradiation and lymphocytes are relatively radiation sensitive.
A common approach to tumor immunotherapy in recent years has been to use tumor cells genetically modified to express cytokine genes. This has been shown frequently in murine models to reduce tumorigenicity, most commonly by activating nonspecific effector mechanisms and, less frequently, by enhancing tumor immunogenicity. 8 -15 Immunization with vaccines of irradiated tumor cells genetically modified to produce certain cytokines has been shown to cure small tumor deposits and prevent the development of metastases. The efficacy of cytokine gene therapy varies considerably from tumor model to tumor model, depending upon the level and type of cytokine being used and upon other variables. However, in a number of situations, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor have shown considerable promise. 11, 12, 16 We have shown that genetic manipulation of murine tumors to express IL-3 results in increased immunogenicity of irradiated tumor cell vaccines and a superior in vivo response of established tumors to local radiation therapy, even though the in vitro response is unaffected. 17 In this study, the ability of systemic immunotherapy using irradiated IL-3 tumor cell vaccines to complement local responses of parental tumors to radiation therapy was investigated. Vaccine-based, tumor-directed cytokine gene therapy frequently fails to generate sufficient immunity to deal with clinically detectable tumor burdens, and radiation therapy might help in this respect. However, the efficacy of radiation therapy might be improved by immunotherapy that could deal with minimal residual and micrometastatic disease.
MATERIALS AND METHODS

Mice
Inbred female C3H/HeN and C3H/HeJ mice were purchased from the National Animal Center (Taipei, Taiwan) and maintained in the department of Atomic Science, (Tsing Hua University). They were 12 weeks old at the beginning of the experiments.
Tumors
A moderately immunogenic methylcholanthrene-induced fibrosarcoma (FSAR) and a nonimmunogenic spontaneous fibrosarcoma (FSAN) that are syngeneic to C3H mice were used. Tumors were generated by inoculating 5 ϫ 10 5 viable FSAR or FSAN cells into the right thighs of mice. Tumors of 8 -9 mm in diameter were irradiated with a single dose of 25 Gy for FSAR tumors and 35 Gy for FSAN tumors using 6 megavolt x-rays from a linear accelerator. The dose rate was 2-3 Gy/minute, there was a 1.5-cm bolus on the surface, and the body, excluding the tumor, was shielded. This would be a relatively high dose if used clinically; more often, fractionated rather than single doses would be given, but the purpose here was simply to demonstrate proof of principle. Mice were inoculated intraperitoneally (i.p.) with 10 6 of 30-Gy irradiated FSAR/FSAN or FSAR-JmIL-3/FSAN-JmIL-3 tumor cells 1 day before irradiation and immediately after irradiation. Boosts of the same sized inocula were given on days 1 and 7. Tumor growth was determined by measuring three mutually orthogonal tumor diameters at 2-3 day intervals with a Vernier caliper and calculating the mean values. Tumor volume was calculated as 4/3 ϫ (diameter/2) 3 . Mice were euthanized when tumors reached 16 mm in diameter.
Gene transduction
The Moloney murine leukemia virus-based vector Jzen0.1 was used to introduce and express the full-length cDNA for murine IL-3 into cultured tumor cells, as described previously. 13 IL-3 gene expression was examined by ribonuclease protection assay (RPA) analysis, and protein production was examined by enzyme-linked immunosorbent assay (Endogen, Boston, Mass). A total of 5 ϫ 10 5 cells produced 34 Ϯ 5 ng/mL (FSAN-JmIL-3) or 38 Ϯ 4 ng/mL (FSAR-JmIL-3) IL-3 in 24 hours. All the experiments in this study have been performed using a control cell line transduced by the same vector containing only a neomycin resistance gene. Because the results were essentially identical with those obtained with the parental line, the data are omitted for the sake of clarity.
RPA
The total RNA was isolated from tumors using single-step acid guanidium thiocyanate-phenol-chloroform extraction. The expression of ILs (IL-1␣/␤, IL-2, IL-3, IL-4, IL-5, and IL-6), interferon-␥, tumor necrosis factor-␣/␤ (TNF-␣/␤), intercellular adhesion molecule-1 (ICAM-1), Mac-1, and inducible nitric oxide synthase (iNOS) was measured by RPA. The templates for making these probes were kindly provided by Dr. I. L. Campbell (Scripps Research Institute, San Diego, Calif). RPA was performed as described previously.
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RESULTS
Effect of FSAR-JmIL-3 tumor vaccine on radiation-induced tumor growth delay
The ability of irradiated tumor cell vaccines, with and without IL-3 gene expression, to influence the response of 8 -9 mm diameter FSAR tumors to a noncurative dose of 25 Gy local irradiation was assessed. A vaccine of irradiated FSAR-JmIL-3 tumor cells was more effective than vaccines of parental FSAR or control FSA-Jneotransfected (data not shown) cells (Fig 1) . Radiationinduced growth delay was increased from 6.7 to 12 days by FSAR vaccine treatment and to 25 days by FSARJmIL-3 vaccination (Table 1) , although complete cures were not achieved. Irradiated FSAN-JmIL-3 cells were less effective than FSAR-JmIL-3 cells at delaying tumor mm in diameter to 25 Gy irradiation. The tumor vaccine was given 1 day before and immediately after irradiation. Boosts of the samesized inocula were given on days 1 and 7. This dose of radiation caused ϳ11 days of growth delay in FSAR parental tumors ( Table  1) . Vaccines of FSAR-JmIL-3 tumor cells were more effective than vaccines of the parental strain. The data presented are the average of five to seven mice for each group from one of two experiments that gave similar results.
regrowth, indicating that tumor-specific immunity was at least in part responsible for the effect.
The failure of vaccines to eliminate established tumors is probably due to the size of the tumor burden. We have shown previously that preimmunization of mice with irradiated FSAR or FSAR-JmIL-3 tumor cell vaccine completely protects against subsequent challenge with 10 6 viable tumor cells. 13 However, against established tumors, FSAR-JmIL-3 tumor vaccines were less effective, giving significant growth delay only if the tumor was Ͻ4 mm in diameter (Fig 2) . These results suggest that tumor vaccination can enhance the effectiveness of radiation therapy, and that IL-3 gene-transduced vaccines may be superior to parental tumor cell vaccines. However, FSAR is an immunogenic tumor, as is seen by the finding that the parental vaccine was effective at delaying tumor growth after irradiation (Fig  1) . The strategy was therefore extended to investigation of a nonimmunogenic tumor. FSAN is nonimmunogenic by the definition that immunization of mice with an irradiated FSAN tumor cell vaccine fails to protect mice from parental viable tumor cell challenge. 13 Effect of FSAN-JmIL-3 tumor vaccine on radiation-induced tumor growth delay Vaccination of mice with irradiated FSAN cells did not increase growth delay after irradiation of 8 -9 mm diameter parental tumors, as would be expected in a nonimmunogenic tumor system. However, FSANJmIL-3 tumor vaccine was effective (Fig 3) , increasing growth delay from 15.47 Ϯ 1.74 to 27.81 Ϯ 4.65 days (Table 1) , although complete cures were not achieved. This result again demonstrates that IL-3 gene transduction can increase the efficacy of tumor cell vaccines, even against a nonimmunogenic tumor, and their systemic administration can enhance the efficacy of radiation therapy. In this case, a vaccine of irradiated FSAR-IL-3 cells had no effect on radiation-induced growth delay of FSAN tumors, indicating tumor specificity. It seems likely that the slight degree of cross-protection seen in Figure 1 with FSAN-IL-3 against FSAR tumors was due Table 1 ). The application of FSAN tumor vaccine did not change this, but longer tumor growth delay was observed in mice treated with FSAN-JmIL-3 tumor vaccine. The data presented are the average of five to seven mice for each group from one of two experiments that gave similar results. to IL-3 boosting a pre-existing state of immunity against this immunogenic tumor.
Molecular events after IL-3 tumor vaccine treatment
We had shown previously that intratumoral (i.t.) IL-3 gene expression led to a massive lymphocytic infiltration into tumors after irradiation and tumor regression. To explore i.t. events after irradiation in animals receiving systemic IL-3-tumor vaccine treatment, mRNA was isolated from tumors at 10 days after treatment and analyzed by RPA. The results (Fig 4A) show increases in the i.t. levels of ICAM-1, iNOS, Mac-1, and EB22/5.3 mRNAs if the mice received systemic FSAR-JmIL-3 vaccination. ICAM-1 is involved in the trafficking of leukocytes into tumors, 19 which could result in the increased expression of Mac-1 and EB22/5.3 mRNAs. Mac-1 is the marker for macrophages. It binds ICAM-1 and mediates several adhesion-dependent processes in leukocytes, such as adhesion to the endothelium, phagocytosis, superoxide production, and other activation events.
20 EB22/5.3 is an acute phase protein that is usually induced during inflammation. 21 Nitric oxide has been proposed to be involved in antitumoral responses in many tumor models, 22, 23 where it is thought to play an effector role. Similar increases in ICAM-1, iNOS, Mac-1, and EB22/5.3 were observed in tumors in mice treated with the FSAN-JmIL-3 tumor vaccine. When a cytokine RPA probe set was used (Fig 4B) , TNF-␣ mRNA was found to be significantly induced in tumors after irradiation, but tumor cell vaccination had no further effect. In contrast, levels of IL-1␤ mRNA were higher in the tumor samples from mice receiving the FSAR-JmIL-3 tumor cell vaccine. The data suggest that systemic vaccination with irradiated IL-3-producing tumor cells enhances the nonspecific i.t. inflammatory response after irradiation.
Dependence of the effectiveness of the FSAN-JmIL-3 tumor vaccine upon TNF-␣ A likely mechanism by which IL-3 enhances antitumoral responses is through activation of antigen (Ag)-presenting cells (APCs). 24 A role for TNF-␣ in this process has been proposed. 25 The lipopolysaccharide (LPS)-hyporesponsive mouse strain (C3H/HeJ) was used to determine whether TNF-␣ is an intermediary required for IL-3-based vaccines to work. These mice fail to produce TNF-␣ in response to LPS, irradiation, and many other stimuli. FSAN-JmIL-3 tumors grown in this mouse strain do not express TNF-␣ mRNA (Fig 5) . FSAN tumors grew slower in this mouse strain before irradiation (Table 1) . When the combination of FSAN-JmIL-3 tumor cell vaccine with irradiation was examined, the vaccine was still effective (Fig 6) , but the tumor growth delay was relatively less in C3H/HeJ mice compared with C3H/HeN mice (12.17 Ϯ 2.33 days versus 27.81 Ϯ 4.65 days) ( Table 1 ). This indicates that TNF-␣ might be involved in IL-3-mediated antitumoral responses.
DISCUSSION
Important questions that impact all strategies for cancer immunotherapy are the extent to which tolerance to tumor Ags exists, whether tolerance develops during tumor growth, whether tolerance can be broken, and the role of cancer-related immune suppression. Many studies have shown that cancers develop systemic specific and nonspecific immune suppression that can inhibit the generation of host antitumoral responses and/or tumor rejection. 26 -29 Biological response modifiers in cancer therapy have to function in this setting, and there is likely to be a window of time in which any immune response can be most effective before suppression is firmly established. Because the rate of tumor cell elimination relative to the rate of tumor cell proliferation is critical for regression to occur, strategies that cause rapid immune activation and rapidly decrease tumor cell numbers are likely to be superior forms of therapy. It would therefore seem reasonable to use radiotherapy to rapidly decrease the tumor burden and possibly remove the suppression associated with large tumor burdens, in combination with gene immunotherapy to boost responses. In this study, we have examined the efficiency of combined IL-3 gene-transduced tumor vaccine therapy and radiotherapy. The mechanisms responsible for the antitumoral effects after IL-3 gene transduction occur through the activation of a subset of small-sized macrophages that are powerful APCs. 16, 24, 30 This subset can generate specific cytotoxic T-lymphocyte and T helper cell responses. 31, 32 We had shown previously that i.t. IL-3 gene expression could enhance tumor responsiveness to irradiation in vivo. 17 This is not because the intrinsic radiosensitivity of the tumor is affected by IL-3. Rather, IL-3 enhances tumor immunity and induces a host cell infiltrate into the tumor that is composed of polymorphonuclear leukocytes and macrophages as well as lymphocytes. After irradiation, the lymphocytic response is particularly marked and is associated with complete tumor regression.
Systemic vaccination procedures are somewhat easier to perform than in situ genetic manipulation of tumors; therefore, this approach was tested for its ability to enhance the efficacy of tumor radiotherapy. IL-3 genetransfected tumor cell vaccines were effective in prolonging tumor growth delay after radiotherapy. This was seen with both an immunogenic tumor (FSAR) and a nonimmunogenic tumor (FSAN). The findings are consistent with our previous report that IL-3 gene transduction can enhance tumor immunogenicity, 13 and with the reports of others. 16, 24, 31, 32 Unlike i.t. IL-3 expression, systemic IL-3 gene-transduced tumor cell vaccination did not result in complete tumor rejection after radiotherapy; only a partial response was observed. However, systemic vaccination may be a feasible approach to eradicate small residual tumor deposits left after radiotherapy, which are responsible for most recurrent and metastatic tumors. It is of interest that IL-3-based tumor vaccines were less effective against nonirradiated tumors that were Ն4 mm in diameter than against irradiated tumors that were considerably larger than 4 mm in diameter. It may be that tumor irradiation enhances the efficacy of tumor vaccination. This enhancement could result from a liberation of additional Ag, allowing access of host cells to the tumor and causing temporarily tumor cell cycle arrest, which would allow antitumoral responses to be more effective, or could result from the induction of cytokines such as TNF-␣ and IL-1, which could act as "danger" signals for immune activation.
In irradiated tumors, i.t. ICAM-1 mRNA was increased in mice receiving IL-3 gene-transduced tumor cell vaccine. Increased ICAM-1 expression is an indication of leukocytic traffic into tumor sites. 19 Although we have not directly demonstrated which cell type expresses ICAM-1 and the involvement of this molecule in trafficking, increased host cell infiltration clearly occurs, as is seen by an increase in i.t. Mac-1, TNF-␣, IL-1␤, and acute phase protein (EB22.5) expression. It is likely that this infiltrate is responsible for the prolongation of radiation-induced tumor growth delay after IL-3 genetransduced tumor vaccine treatment. What was conspicuous by its absence was evidence for lymphocytic cytokines such as IL-2 or IL-4, which would indicate a heavy lymphocytic infiltrate, as was seen when IL-3 was expressed within the tumor. Locally high IL-3 concentrations may be needed to alter the tumor microenvironment and facilitate this response. Nevertheless, this study demonstrates that the administration of tumor vaccine i.p. can lead to host cell infiltration and inflammatory responses in the primary tumor site that at least in large part function in a tumor-specific manner.
IL-3 is known to participate in determining the development and functional behavior of macrophages. 33, 34 Lord and colleagues 31, 35 have recently shown that IL-3-induced macrophages have an enhanced ability to present ovalbumin Ag in the context of major histocompatibility complex class molecules to CD8 ϩ cytotoxic T lymphocytes. IL-3 also co-operates with TNF-␣ to induce the growth of dendritic cells, which are professional APCs. 25 In this study, we used an LPS-hyporesponsive mouse model (C3H/HeJ) to demonstrate that a deficit in TNF-␣ decreases, but does not abolish, the effectiveness of FSAN-JmIL-3 tumor cell vaccines. The defect in this mouse strain has been variably ascribed to a missense mutation of the Toll-like receptor-4 gene 36 or to overexpression of secretary leukocyte protease inhibitor and matrix metalloprotease-9. 37, 38 Although the exact mechanism is unclear, it is likely that TNF-␣ may cooperate with IL-3, but is not essential for its effects in enhancing tumor immunity.
In summary, this study demonstrates that the efficacy of radiation therapy is enhanced by systemic administration of IL-3 gene-transfected tumor cell vaccines. Conversely, the efficacy of systemic tumor cell vaccination is enhanced by local tumor radiation therapy. Although i.t. expression of IL-3 may be more effective than systemic vaccination, systemic vaccination is easier to perform and may eliminate small local tumor deposits such as might remain after radiotherapy or be present as micrometastases. Combining radiotherapy with cytokinebased gene therapy seems to be a logical approach for improving the efficacy of cancer therapy. A similar conclusion was also recently demonstrated by Seetharam et al using the approach of i.t. injection of an adenoviral vector with IL-12, 39 although the working mechanisms might be different in these two cytokines.
